Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M93,386Revenue $M19,960Net Margin (%)8.9Z-Score3.4
Enterprise Value $M95,699EPS $1.1Operating Margin %17.1F-Score5
P/E(ttm))53.5Cash Flow Per Share $0Pre-tax Margin (%)11.9Higher ROA y-yN
Price/Book53.610-y EBITDA Growth Rate %0Quick Ratio1.3Cash flow > EarningsY
Price/Sales4.75-y EBITDA Growth Rate %0Current Ratio1.4Lower Leverage y-yY
Price/Cash Flow0y-y EBITDA Growth Rate %-45.1ROA % (ttm)6.2Higher Current Ratio y-yN
Dividend Yield %3.0Insider Buy (3m)0ROE % (ttm)42.7Less Shares Outstanding y-yN
Payout Ratio %151Shares Outstanding M1,594ROI % (ttm)22.2Gross Margin Increase y-yY

Gurus Latest Trades with ABBV

Number of guru portfolios checked: 84. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
ABBVLee Ainslie 2014-12-31 Sold Out -4%$52.9 - $69.71
($63.24)
$ 58.59-8%Sold Out0
ABBVJohn Paulson 2014-12-31 Sold Out -3.1%$52.9 - $69.71
($63.24)
$ 58.59-8%Sold Out0
ABBVAndreas Halvorsen 2014-12-31 Sold Out -2.5%$52.9 - $69.71
($63.24)
$ 58.59-8%Sold Out0
ABBVSteve Mandel 2014-12-31 Sold Out -1.2%$52.9 - $69.71
($63.24)
$ 58.59-8%Sold Out0
ABBVGeorge Soros 2014-12-31 Sold Out -0.66%$52.9 - $69.71
($63.24)
$ 58.59-8%Sold Out0
ABBVJean-Marie Eveillard 2014-12-31 Buy 0.16%$52.9 - $69.71
($63.09)
$ 58.59-8%New holding1,016,097
ABBVMario Gabelli 2014-12-31 Add0.01%$52.9 - $69.71
($63.09)
$ 58.59-8%Add 232.85%34,557
ABBVJohn Paulson 2014-09-30 Buy 3.1%$52.05 - $59.62
($55.51)
$ 58.595%New holding13,000,000
ABBVAndreas Halvorsen 2014-09-30 Buy 2.5%$52.05 - $59.62
($55.51)
$ 58.595%New holding10,769,105
ABBVLee Ainslie 2014-09-30 Add1.26%$52.05 - $59.62
($55.51)
$ 58.595%Add 46.01%4,723,578
ABBVSteve Mandel 2014-09-30 Buy 1.2%$52.05 - $59.62
($55.51)
$ 58.595%New holding5,247,201
ABBVJohn Hussman 2014-09-30 Reduce-0.87%$52.05 - $59.62
($55.51)
$ 58.595%Reduce -66.67%100,000
ABBVGeorge Soros 2014-09-30 Add0.6%$52.05 - $59.62
($55.51)
$ 58.595%Add 924.76%1,537,146
ABBVJoel Greenblatt 2014-09-30 Reduce-0.06%$52.05 - $59.62
($55.51)
$ 58.595%Reduce -89.36%9,460
ABBVLee Ainslie 2014-06-30 Buy 2.6%$46.46 - $56.79
($52.4)
$ 58.5911%New holding3,235,133
ABBVJoel Greenblatt 2014-06-30 Reduce-0.11%$46.46 - $56.79
($52.4)
$ 58.5911%Reduce -61.19%88,923
ABBVGeorge Soros 2014-06-30 Reduce-0.1%$46.46 - $56.79
($52.4)
$ 58.5911%Reduce -57.14%150,000
ABBVKen Fisher 2014-06-30 Add0.06%$46.46 - $56.79
($52.4)
$ 58.5911%Add 76.13%1,104,609
ABBVNWQ Managers 2014-06-30 Buy 0.05%$46.46 - $56.79
($52.4)
$ 58.5911%New holding83,878
ABBVGeorge Soros 2014-03-31 Reduce-0.35%$46.83 - $53.68
($50.6)
$ 58.5914%Reduce -69.50%350,000
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

ABBV is held by these Gurus:

Premium Most recent portfolio changes are included for Premium Members only!


ABBV: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Schumacher Laura JEVP, Bus.Dev.,Ext.Aff.&GC 2015-03-02Sell25,000$60.3-5.02view
RICHMOND TIMOTHY J.SVP, Human Resources 2015-03-02Sell14,388$60.33-5.07view
SALEKI-GERHARDT AZITASVP, Operations 2015-02-27Sell2,112$60.47-5.29view
HURWICH THOMAS A.VP, Controller 2015-02-27Sell1,185$60.57-5.45view
RICHMOND TIMOTHY J.SVP, Human Resources 2015-02-17Sell241$58.7-2.44view
CHASE WILLIAM JEVP, CFO 2014-12-22Sell8,495$68-15.78view
HURWICH THOMAS A.VP, Controller 2014-11-24Sell1,500$67.81-15.54view
GONZALEZ RICHARD AChairman of the Board and CEO 2014-03-04Sell4,799$51.211.86view
ALBAN CARLOSEVP, Commercial Operations 2014-03-03Sell2,882$50.0914.33view
CHASE WILLIAM JEVP, CFO 2014-03-03Sell3,948$50.2214.04view

Press Releases about ABBV :

    Quarterly/Annual Reports about ABBV:

    News about ABBV:

    Articles On GuruFocus.com
    AbbVie Strikes The Biggest Deal For Treatment Of Cancer Mar 10 2015 
    Top Stock Picks Among Companies That Recently Increased Dividends Mar 09 2015 
    AbbVie To Acquire Biopharmaceutical Firm Pharmacyclics Mar 06 2015 
    Cracking The Best Healthcare Dividend Stock Secrets Mar 02 2015 
    Dogs Of The S&P 500 - No Dividend Alternatives Are Cheaper! Feb 22 2015 
    Achillion Pharmaceuticals Stock Soars Following Successful Mid-Stage Hep C Drug Combo Trial Feb 10 2015 
    Gilead Sciences Offering Fresh Wave Of Competition To AbbVie’s Viekira Pak Feb 06 2015 
    Gilead Sciences Falls 10% After More Than Doubling Drug Discounts For 2015 Feb 05 2015 
    The Gabelli ABC Fund Merger and Arbitrage – “The Deal Fund” Q4 Commentary Feb 04 2015 
    AbbVie’s Q4 Reflects Its Tremendous Growth Potential Going Forward Feb 04 2015 


    More From Other Websites
    Transaction Basics of the Life Time Fitness Merger Mar 26 2015
    Read This Before You Sell Gilead Sciences Mar 25 2015
    4 Top-Ranked Health Care ETFs for a Healthy Portfolio - ETF News And Commentary Mar 25 2015
    Biotech Stock Roundup: Biogen Soars on Alzheimer's Data, Gilead HCV Drugs Label Update - Analyst... Mar 25 2015
    The Pharmacyclics–AbbVie Merger: The Basics of Pharmacyclics Mar 25 2015
    Google-backed aging research company Calico cuts local research deal Mar 24 2015
    Why All Those Testosterone Ads Constitute Disease Mongering Mar 24 2015
    Could the Pharmacyclics–AbbVie Merger Get Competitive? Mar 24 2015
    Edeleman, iShares Launch Exponential Technologies ETF Mar 24 2015
    Edelman, iShares Launch Exponential Technologies ETF Mar 24 2015
    TG Therapeutics Is A Best Idea Mar 24 2015
    New Alzheimer's Research Throws Cold Water on Biogen's Recent Breakthrough Mar 23 2015
    Gilead: Buy the Pullback Mar 23 2015
    Gilead shares dip after warning about hepatitis C drug interaction Mar 23 2015
    Is Antitrust a Risk in the Pharmacyclics–AbbVie Merger? Mar 23 2015
    Pharmacyclics chief to receive $3.6bn from takeover Mar 23 2015
    Gilead Sciences' Hepatitis-C Warning a 'Non-Event,' 'Buy on Weakness' Mar 23 2015
    Rationale for the Pharmacyclics–AbbVie Merger Mar 23 2015
    Big Pharma But Not Such Big Money Mar 23 2015
    Cramer's stocks to watch: Amazing biotech Mar 23 2015

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    Free 7-day Trial
    FEEDBACK